Galway, Ireland Jan 1- AOTI, Ltd., announced today that it has formalized a strategic partnership agreement and exclusive worldwide distribution rights for wound care and exclusive European rights for Respiratory care with Sequal Technologies (SeQual) of San Diego, CA.
“Today’s partnership brings together two companies whose products benefit patients suffering from chronic wounds, such as diabetic, venous and pressure ulcers as well as those from COPD. These chronic conditions collectively impact millions of patients each year and the overlap between COPD and diabetes is well documented in peer review. By combining our sales, service, and clinical resources we feel confident in offering the European market better overall support.” said Mike Griffiths, President and CEO of AOTI.
Griffiths added, “The combination of SeQual’s products along with our wound care line will allow for our unique Topical Wound Oxygen therapy to be applied in all care sites including the patient’s home. The natural synergies between our two companies offer exciting mutual benefits for all of our existing, as well as, future customers and partners.”
AOTI is founded on a decade of experience in providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (two2) therapy is unsurpassed in fully closings Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net. “The Eclipse 2 with AutoSAT™ offers a compelling alternative to other oxygen solutions and we are delighted to be adding the PAOS to our product portfolio” said Kevin Plihal, VP Global Business Development for AOTI.
